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Pseudomonas aeruginosa is an opportunistic pathogen that causes frequently nosocomial
infections, currently becoming more difﬁcult to treat due to the various resistance mech-
anisms and different virulence factors. The purpose of this study was to determine the
risk factors independently associated with the development of bacteremia by carbapenem-
resistant P. aeruginosa, the frequency of virulence genes in metallo--lactamases producers
and  to evaluate their ability to produce bioﬁlm. We  conducted a case–control study in
the  Uberlândia Federal University – Hospital Clinic, Brazil. Polymerase Chain Reaction
was  performed for metallo--lactamases and virulence genes. Adhesion and bioﬁlm
assays were done by quantitative tests. Among the 157 strains analyzed, 73.9% were
multidrug-resistant, 43.9% were resistant to carbapenems, 16.1% were phenotypically
positive for metallo--lactamases, and of these, 10.7% were positive for blaSPM gene and
5.3% positive for blaVIM. The multivariable analysis showed that mechanical ventilation,
enteral/nasogastric tubes, primary bacteremia with unknown focus, and inappropriate
therapy were independent risk factors associated with bacteremia. All tested strains were
characterized as strongly bioﬁlm producers. A higher mortality was found among patients
with  bacteremia by carbapenem-resistant P. aeruginosa strains, associated independently
with extrinsic risk factors, however it was not evident the association with the presence of
virulence and metallo--lactamases genes.© 2016 Sociedade Brasileira de Microbiologia. Published by Elsevier Editora Ltda. This is
s arti
these resistant microorganisms are often associated with age,an  open acces
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ealthcare-associated infections (HAIs) like bacteremia
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hospitalization, and higher costs compared to those infec-
tions caused by susceptible strains.1–3 Infections caused byistant Pseudomonas aeruginosa:  association with virulence genes and
16.11.004
e, 1720 Umuarama, Uberlândia, MG, Brazil.
cancer, heart disease, diabetes, intensive use of antibiotics,
and invasive procedures such as hemodialysis, mechanical
ventilation catheter, tracheostomy, and others.4
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.
ARTICLE IN PRESSBJM-186; No. of Pages 7
 c r o b2  b r a z i l i a n j o u r n a l o f m i
The increasing incidence of multidrug-resistant P. aerugin-
osa as a cause of nosocomial infection is a global problem, a
consequence of the ability of this microorganism to develop
resistance to almost all other antimicrobial agents during
antimicrobial chemotherapy, either by selection of mutations
in chromosomal genes or by horizontal gene transfer.5,6 In
Brazil, this problem is even more  signiﬁcant, since there is
a very high density of antibiotic use, especially -lactams,
carbapenems, and ﬂuoroquinolones.7,8 The resistance in P.
aeruginosa to carbapenems is up to 60% in some Brazilian
hospitals9,10 and mainly occurs by production of metallo--
lactamases (MBL).
Ten subclasses of the MBL  enzymes are known: IMP
(Imipenemase), VIM (Verona Imipenemase), SPM-1 (São
Paulo MBL), GIM (German Imipenemase), SIM-1 (Seul
Imipenemase),11 AIM-1 (Australian Imipenemase),12 KHM
(Kyorin University Hospital),13 NDM-1 (New Delhi MBL),14
DIM-1 (Dutch Imipenemase),15 and TMB  (Tripoli MBL).16 In
Brazil, the most prevalent subclasses are IMP-1 and SPM-1.11
Several other virulence genes as well as bioﬁlm formation
may contribute to the pathogenicity of severe infec-
tions, particularly including those associated with invasive
procedures.17 Among the major virulence factors described
in the literature, we highlight those related to the adher-
ence of microorganisms to host cells through the ﬂagella,
ﬁmbriae, and alginate18 and those that facilitate the disrup-
tion of epithelial integrity and interfere with the immune
system, such as elastase, phospholipase C and protease alka-
line, further exotoxin A, pyocyanin, and pyoverdine.19 The
bioﬁlm production is particularly associated with the difﬁ-
culty of antibiotics to penetrate the cells, since them secrete a
polymeric matrix composed of polysaccharides, proteins, and
DNA.20,21
The aim of this study was to identify the risk factors asso-
ciated with bacteremia caused by carbapenem-resistant P.
aeruginosa as well as the production of MBL. Additionally, we
investigated the frequency of virulence genes and their ability
to form bioﬁlm.
Materials  and  methods
Patients  and  hospital
The P. aeruginosa strains were recovered from patients admit-
ted to the Uberlandia University Hospital (Brazil), Federal
University of Uberlândia (HC-UFU), and obtained from the
Microbiology Laboratory of the HC-UFU, during the period
from May 2009 to December 2012, considering only the ﬁrst
episode of infection.
Study  design
We  conducted a case (patients with bacteremia due to P. aeru-
ginosa resistant to carbapenems) versus control (patients with
bacteremia caused by P. aeruginosa susceptible to carbapen-Please cite this article in press as: Rossi Gonc¸alves I, et al. Carbapenem-re
bioﬁlm formation. Braz J Microbiol. (2016), http://dx.doi.org/10.1016/j.bjm.20
ems) study to identify risk factors among patients infected
with P. aeruginosa resistant to carbapenems. Additionally, we
evaluated secondary outcomes, including periods of hospital-
ization, admission to the intensive care unit (ICU), and use of i o l o g y x x x (2 0 1 6) xxx–xxx
invasive procedures. Demographic, clinical, and epidemiolog-
ical characteristics of each patient included in the study were
recovered from the clinical records.
Deﬁnitions
Healthcare-associated infections (HAIs) are deﬁned as any
infection acquired after a patient’s admission to the hospital.
HAIs may manifest during hospitalization or after discharge,
since they are related to hospitalization or procedures per-
formed during the hospitalization.22 Bacteremia, according
to the Centers for Disease Control and Prevention,23 can be
deﬁned as the presence of viable bacteria in the blood doc-
umented by a positive blood culture result. Bacteremia was
classiﬁed as primary when it was unrelated to another focus
of infection or when it was related to an intravenous catheter,
and secondary when it was clinically related to infection in
another anatomic site.9 Multidrug-resistance is deﬁned as
acquired non-susceptibility to at least one agent in three or
more  antimicrobial categories.24 The antimicrobial therapy
was considered inappropriate when an isolated microorgan-
ism presented in vitro resistance to antimicrobials used for
treating the patient and/or a lack of treatment for 24 h after
diagnosis of microbial infections.25
Clinical  microbiological  and  molecular  testing
Cultures were collected according to the protocol used by the
Microbiology Laboratory of the HC-UFU and were processed
using the automated system BACT/Alert
®
(BioMérieux,
Durham, USA). The identiﬁcation and antimicrobial suscep-
tibility tests were performed by automation using the VITEK II
system and the strains that showed intermediate susceptibil-
ity were considered resistant. Quality-control protocols were
used according to the standards of the Clinical and Laboratory
Standard Institute.26–28 The carbapenem-resistant P. aerugin-
osa isolates were phenotypically screened for MBL production
using double-disc synergy tests, as previously described.29,30
In addition, to assess the presence of MBL  genes in P. aeru-
ginosa strains, a multiplex PCR was performed, as described
previously.31 The cycling conditions were: 94 ◦C for 5 min,
followed by 30 denaturation cycles at 94 ◦C for 30 s, anneal-
ing at 53 ◦C for 45 s and extension at 72 ◦C for 30 s, followed
by ﬁnal extension at 72 ◦C at 10 min, all in a MasterCycler
personal (Eppendorf). Detection of virulence genes codifying
alkaline protease (aprA), elastase A (lasA), elastase (lasB),32
haemolytic phospholipase C (plcH), non-haemolytic phospho-
lipase C (plcN), exotoxin A (toxA) and alginate (algD)33 were
determined by uniplex PCR, using the following protocol: 94 ◦C
for 3 min, 30 cycles at 94 ◦C for 30 s, 55 ◦C for 1 min  and 72 for
1 min  and 30 s and 72 ◦C for 5 min.
Initial  adhesion  assay34
In order to evaluate the initial adhesion, 200 L of a cell
suspension containing 1 × 107 cells/mL prepared in TSB wassistant Pseudomonas aeruginosa:  association with virulence genes and
16.11.004
added to 96-well polystyrene plates. Initial adhesion was
allowed to occur for 2 h at 37 ◦C with rotation at 120 rpm.
Bacteria adhered in 96-well polystyrene plates were washed
twice with a 0.9% NaCl solution and harvested by scraping the
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Table 1 – Distribution of patients infected with
Pseudomonas aeruginosa in different units of the Clinical
Hospital of the Federal University of Uberlândia from
May/2009 to December/2012.
Clinics Total Carbapenem-resistant
Pseudomonas aeruginosa
N = 157 (%) N = 69 (%)
Surgery 35 (22.3) 16 (23.2)
Medical clinic 24 (15.3) 10 (14.5)
Oncology 14 (8.9) 2 (2.9)
Emergency room 9 (5.7) 5 (7.3)
ICUa 50 (31.9) 31 (44.9)
Neonatal ICU 2 (1.3) 0
Pediatric ICU 2 (1.3) 1 (1.5)
Transplant 2 (1.3) 0
Othersb 3 (1.9) 0
a Intensive care unit.b  r a z i l i a n j o u r n a l o f m i c
ells for 90 s. The cell suspension obtained was plated on TSA
or colony-forming unit (CFU) enumeration. All experiments
ere done in triplicate in three independent experiments. The
train ATCC15692 (PAO1) was used as a positive control and
SB without bacteria was used as a negative control.
ioﬁlm  formation  assay35
00 L of a cell suspension containing 1 × 107 cells/mL pre-
ared in TSB was added to 96-well polystyrene plates. Bioﬁlm
ormation was allowed to occur for 24 h at 37 ◦C with rota-
ion at 120 rpm. Bacteria grown in 96-well polystyrene plates
ere washed twice with a 0.9% NaCl solution and left to
ry in an inverted position. The total biomass was measured
y methanol (Merck) ﬁxation, crystal violet (Merck) stain-
ng, and acid acetic (Merck) elution as previously described.
he eluted dye was removed from each well and placed
n a new 96-well microtiter plate, and its absorbance was
ead on an ELISA plate reader (BioTek Instruments Inc., Ver-
ont, USA) at 570 nm.  The experiments were done with
ight replicates for each strain in three independent experi-
ents. TSB without bacteria was used as a negative control.
he optical density cut-off value (ODc) was established as
hree standard deviations (SD) above the mean of the opti-
al density (OD) of the negative control: ODc = average OD of
egative control + 3x SD of negative control. For easier inter-
retation of the results, strains were divided into the following
ategories according to optical density: (ODi): ODi ≤ ODc or
Dc < ODi < 2x ODc = non-bioﬁlm producer/weak bioﬁlm pro-
ucer; 2x ODc < ODi < 4x ODc = moderate bioﬁlm producer; 4x
Dc < ODi = strong bioﬁlm producer.
ioﬁlm  cell  concentration36
he bioﬁlm cell concentration was determined by CFU enu-
eration. After bioﬁlm formation, the bioﬁlms were washed
wice with a 0.9% NaCl solution and harvested after scraping
he wells for 90 s. The cell suspension obtained was plated
nto TSA plates. All experiments were done in triplicate, on
hree independent occasions.
tatistical  analysis
tatistical analysis was performed using GraphPad Prism v.5
GraphPad Software, San Diego, CA). Quantitative assays were
ompared using the Kruskal–Wallis, applying Dunn’s multiple
omparison test. All tests were performed with a conﬁdence
evel of 95% and statistical signiﬁcance was deﬁned as p < 0.05.
thical  approval
he research Ethics Committee of the Federal University Uber-
andia evaluated and approved our study design.
esultsPlease cite this article in press as: Rossi Gonc¸alves I, et al. Carbapenem-res
bioﬁlm formation. Braz J Microbiol. (2016), http://dx.doi.org/10.1016/j.bjm.20
rom May 1, 2009, to December 31, 2012, a hospital surveillance
f the incidence of P. aeruginosa bacteremia was performed
n the microbiology laboratory of the University Hospital.b Burneds, thoracic pain unit.
In this period, 157 non-repetitive patients with P. aerugin-
osa bacteremia were included in the study. The detailed
information on factors associated with the development of
bacteremia and the clinical and demographic characteristics,
as well the distribution of patients by wards are shown in
Tables 1 and 2. The primary bacteremia occurred in 75.8%
and those with unknown focus accounted in 62.4% of the
cases. Secondary bacteremia accounted for 24.2% of patients,
where the respiratory tract was the main focus of infection
(17.2%). Furthermore, 43.9% of patients had bacteremia with
carbapenem-resistant P. aeruginosa,  and most of these patients
were admitted to the ICU. Most patients were male (66.8%),
with an average hospital stay of 63.2 ± 80.17 days and an aver-
age age of 52.01 ± 20.24 years.
The previous use of antibiotics (78.3%), invasive proce-
dures (88.5%), comorbidities (77.7%), and prior surgery (43.9%)
were common. It was found that 31.2% of patients received
inadequate treatment, and the death rate was 58.6%. Several
intrinsic and extrinsic factors for the development of bac-
teremia by strains of P. aeruginosa resistant to carbapenems
were detected by univariate analysis. However, only mechani-
cal ventilation, enteral/nasogastric tubes, primary bacteremia
with unknown focus, and inappropriate therapy were risk
factors independently associated with the development of
carbapenem-resistant P. aeruginosa bacteremia.
MBL production was analyzed for 56 carbapenem-resistant
P. aeruginosa isolates. Nine (25.0%) isolates were phenotypically
positive and a total of 16.1% (n= 9/56) were consistent with the
amplicons MBL genes, being 10.71% blaSPM-1 and 5.3% blaVIM
genes In general, the strains showed a multidrug resistance
proﬁle. For other virulence genes evaluated (aprA, plcH, plcN,
lasA, lasB, toxA, and algD), all strains showed a high frequency
(88%).
Among the 88 carbapenem-susceptible P. aeruginosa
strains, 21 (23.9%) were resistant to other -lactams. For 69
strains resistant to carbapenems, the resistance proﬁle was
high: -lactam 50/69 (72.5%), ﬂuoroquinolones 48/69 (69.6%),istant Pseudomonas aeruginosa:  association with virulence genes and
16.11.004
and aminoglycosides 50/69 (72.5%) (Table 3).
In addition to MBL research, ﬁve strains were selected
(two containing SPM-1, one containing VIM, and two
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Table 2 – Risk factors associated with carbapenem resistance in patients with bacteremia caused by Pseudomonas aeruginosa.
Risk factors Total Carbapenem resistant Multisensitivea Univariate Multivariate
N = 157 (%) N = 69 (%) N = 65 (%) ORb (CIc 95%) pd OR (CI 95%) p
Age-mean (years) 52.01  ± 24.49 59.01 ± 20.24 43.18 ± 27.56 – 0.0009* –  –
Male/female 105/52 (66.88/33.12) 45 (65.22)/24 (34.78) 43 (66.15)/22 (33.85) 0.9593 (0.4698–1.959) 0.9092 –  –
Time of hospitalization, mean (days) 63.2  ± 80.17 60.01 ± 48.97 68.86 ± 110.4 – 0.3477 –  –
Intensive care unit 74  (47.13) 38 (55.07) 22 (33.85) 2.396 (1.190–4.822) 0.0135 –  –
Surgery 69 (43.95) 37 (53.62) 20 (30.77) 2.602 (1.281–5.282) 0.0075* –  –
Invasive procedures (72 h) 139 (88.53) 64 (92.75) 54 (83.08) 2.607 (0.8527–7.973) 0.0843 –  –
Mechanical ventilation 89 (56.69) 48 (69.56) 28 (43.08) 3.020 (1.485–6.144) 0.002* 3.0674 (1.22–7.73) 0.0175
Tracheostomy 70 (44.58) 43 (62.32) 17 (26.15) 4.670 (2.234–9.759) <0.0001* –  –
Urinary catheter 101 (64.33) 52 (75.36) 34 (52.31) 2.789 (1.340–5.804) 0.0054* –  –
Venous central catheter 125 (79.62) 59 (85.51) 48 (73.85) 2.090 (0.8761–4.984) 0.0926 –  –
Surgical drain 24 (15.29) 14 (20.29) 7 (10.77) 2.109 (0.7918–5.618) 0.1297 –  –
Probes enteral/gastric nutrition 109 (69.43) 54 (78.26) 40 (61.54) 2.250 (1.053–4.810) 0.0345* 3.8347 (1.43–10.26) 0.0074
Hemodialysis 39 (24.84) 27 (39.13) 8 (12.31) 4.580 (1.892–11.09) 0.0004*
Parenteral nutrition 25 (1.92) 14 (20.29) 8 (12.31) 1.814 (0.7052–4.664) 0.2125 –  –
Comorbidity conditions 122 (77.70) 53 (76.81) 49 (75.38) 1.082 (0.4886–2.394) 0.8465 –  –
Heart failure 35 (22.29) 21 (30.43) 12 (18.46) 1.932 (0.8597–4.343) 0.1079 –  –
Cancer 32 (20.38) 8 (11.59) 17 (26.15) 0.3703 (0.1473–0.9308) 0.0306 –  –
Diabetes mellitus 21 (13.37) 9 (13.04) 7 (10.75) 1.243 (0.4341–3.558) 0.6849 –  –
Chronic renal failure 40 (25.48) 21 (30.43) 16 (24.61) 1.340 (0.6249–2.873) 0.4514 –  –
Human immunodeﬁciency virus 10 (6.37) 5 (7.25) 3 (4.61) 1.615 (0.3699–7.048) 0.7191 –  –
ASISe score ≥ 4 81 (51.59) 35 (50.72) 33 (50.77) 0.9982 (0.5068–1.966) 0.9959 –  –
Primary bacteremia 119 (75.79) 45 (65.22) 57 (87.69) 0.2632 (0.1080–0.6413) 0.0023* –  –
Central line catheter related 21 (13.37) 11 (15.94) 7 (10.75) 1.571 (0.5693–4.338) 0.3802 –  –
Unknown 98 (62.42) 34 (49.27) 50 (76.9) 0.2914 (0.1383–0.6143) 0.0009 0.2363 (0.08–0.73) 0.0127
Secondary bacteremia 38 (24.20) 24 (34.78) 8 (12.31) 3.800 (1.559–9.260) 0.0023* –  –
Respiratory tract 27 (17.19) 17 (24.64) 5 (7.69) 3.923 (1.353–11.37) 0.0081* –  –
Urinary tract 6 (3.82) 4 (5.79) 1 (1.54) 3.938 (0.4282–36.22) 0.3666 –  –
Inappropriate therapy 49 (31.21) 32 (46.37) 8 (12.31) 6.162 (2.560–14.83) <0.0001* 8.5534 (3.28–22.32) <0.0001
Previous use of antibiotics 123 (78.34) 59 (85.51) 43 (66.15) 3.019 (1.297–7.025) 0.0086* –  –
Mortality 92 (58.59) 48 (69.56) 32 (49.23) 2.357 (1.163–4.779) 0.0165* 2.3660 (1.15–4.85) 0.0186
a Multisensitive strains were considered as those who presented susceptibility to all antimicrobials tested.
b Odds ratio.
c Conﬁdence interval.
d p value.
e Average severity of illness score.
∗ Statistically signiﬁcant (P≤0.05).
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Table 3 – Antimicrobial resistance proﬁles in samples of Pseudomonas aeruginosa isolated from blood.
Antimicrobial Carbapenems p (OR)
Resistant group
N = 69 (%)
Susceptible group
N = 88 (%)
Ceftazidime 51 (73.9) 10 (11.4) <0.0001 (9.446–51.71)
Cefepime 45 (65.2) 17 (19.3) <0.0001 (3.792–16.17)
Piperacillin/tazobactam 37 (53.6) 12 (13.6) <0.0001 (3.386–15.84)
Fluorquinolones (ciproﬂoxacin and levoﬂoxacin) 48 (69.6) 17 (19.3) <0.0001 (4.568–19.95)
Aminoglicosides (amikacin and gentamicin) 50 (72.5) 12 (13.6) <0.0001 (7.442–37.32)
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Fig. 1 – (A) Number of cells adhered to a polystyrene surface after 2 h, expressed as log CFU/mL for 5 samples of
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xpressed as optical density of crystal violet (OD570nm).
henotypically positive for MBL) to the evaluation of the
ioﬁlm formation using quantitative assays of total biomass
y staining with crystal violet. Considering the presence of
BL  genes, all strains were identiﬁed as strongly bioﬁlm pro-
ucers with an average of 0.90 ± 0.61 of biomass. Differences in
nitial adhesion of individual strains were not observed. How-
ver, there was a lower OD for the strain containing the blaVIM
ene (Fig. 1).
iscussion
ospital bacteremia caused by multiresistant microorgan-
sms, whether Gram-positive or Gram-negative, has often
een described as a signiﬁcant health problem that increases
ospital costs and makes it difﬁcult to establish an appropriate
ntimicrobial therapy, which results in a worse prognosis.37
he high proportion of hospital bacteremia caused by P. aeru-
inosa resistant to carbapenems indicates the importance of
his organism as a signiﬁcant cause of this infection in our hos-
ital. The high proportion of hospital bacteremia caused by P.
eruginosa resistant to carbapenems indicates the importance
f this organism as a signiﬁcant cause of this infection in our
ospital. The results of different studies have suggested that
ntrinsic risk factors such as mechanical ventilation, use of a
asogastric tube, and prior use of antibiotics increase the risk
f bacteremia development caused by P. aeruginosa resistant to
arbapenems, as well as the risk of morbidity and mortality.38
In this study, more  than 50% of the risk factors were
ssociated with infection by this microorganism accordingPlease cite this article in press as: Rossi Gonc¸alves I, et al. Carbapenem-res
bioﬁlm formation. Braz J Microbiol. (2016), http://dx.doi.org/10.1016/j.bjm.20
o univariate analysis. However, only mechanical ventilation,
nteral/gastric feeding tubes, primary bacteremia of unknown
rigin, and inappropriate treatment were considered indepen-
ent risk factors by multivariate analysis.e cells in the bioﬁlm (log CFU/mL). (C) Biomass of bioﬁlm
A central venous catheter is one of the most signiﬁcant risk
factors for acquired bacteremia in the hospital, as it was asso-
ciated with more  than 90% of these infections.39 Although it
was not a signiﬁcant risk factor in this study, 85.5% of patients
with bacteremia with carbapenem-resistant P. aeruginosa had
this invasive procedure.
Often, bacteremia caused by P. aeruginosa resistant to
antibiotics has a higher mortality rate due, in particular, to the
administration of inappropriate antibiotic therapy.40 In this
study, we investigated a cohort of 157 patients with bacteremia
caused by P. aeruginosa strains, with 69 of them infected by
carbapenem-resistant P. aeruginosa isolates. Total mortality
was higher in the carbapenem-resistant group; however, the
presence of resistant strains was signiﬁcantly associated with
inappropriate antimicrobial therapy, proving that this group
usually has a poorer prognosis. Similar to our ﬁndings, previ-
ous studies showed that P. aeruginosa isolated from patients
who received inappropriate therapy had a worse prognosis,
with rates of 46.1%41 and 53.8%.42
Besides to be associated with severe infections, resistance
to carbapenems in P. aeruginosa often results in the production
of MBL.43 Our results showed that the carbapenem-resistant P.
aeruginosa were prevalent throughout the hospital with genes
that encoding these enzymes in 16.1% of the strains, being
10.7% of genotype blaSPM-1 and 5.4% of genotype blaVIM. Since
the frequency of multidrug-resistant strains was high, these
results suggest that other resistance mechanisms coexist in
these strains, such as efﬂux pumps and impermeability of the
membrane.44
The prevalence of MBL as a resistance mechanism has
45istant Pseudomonas aeruginosa:  association with virulence genes and
16.11.004
increased, particularly in Latin America. In Brazil, the preva-
lence of MBL-producing P. aeruginosa varies between different
regions and between hospitals, with rates ranging from 7.5%
to 44%.11
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SPM-1 enzyme is considered the most common in Brazil,
followed by IMP-1,11,46 however, there has also been an
increase in the frequency of P. aeruginosa isolates containing
VIM enzyme.45,47 In our study, the SPM-1 enzyme was detected
in 16.7% of phenotypically producing samples of MBL, followed
by VIM enzyme, which was detected in 8.3% of cases. These
results indicate a signiﬁcant spread of MBL-encoding genes in
our region.
Considering the presence of MBL  and bioﬁlm produc-
tion, 100% of the strains were classiﬁed as strong producers.
Another study in Brazil found that 40% of P. aeruginosa clas-
siﬁed as strong bioﬁlm-producing were also MBL  producers.35
We  believe that these results are important once these charac-
teristics (bioﬁlm production and MBL) overlap and infections
caused by these bacteria are difﬁcult to treat. This is justiﬁed,
in part, because the growth of bacteria in the bioﬁlm is about
64 times more  resistant to antimicrobial.48
P. aeruginosa has a large number of extracellular virulence
factors that also contribute to the pathogenicity and severity
of these infections, such as that encoded by aprA, plcH, plcN,
lasA, lasB, toxA, and algD genes.32,33 Our data showed that the
presence of a multiresistant proﬁle, in the most of the strains
(88%) were positive for the aprA, plcH, plcN, lasA, lasB, toxA, and
algD virulence genes, except in one strain that did not show the
toxA and plcH genes, which can further contribute to a worse
prognosis associated with severe infections.
Our results conﬁrm previous ﬁndings regarding risk fac-
tors for the development of P. aeruginosa carbapenem-resistant
bacteremia, as well as the dissemination of MBL-producing
strains of SPM-1 type. However, this study contributes for
further evidence of the spread of MBL-producing strains, par-
ticularly the VIM type, in highly virulent strains and strongly
bioﬁlm producers.
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